ClinicalTrials.gg
TerminatedNCT01919190TRANSCENDUpdated Jul 2, 2021Results posted

EXPAREL Administered by Infiltration Into the TAP for Prolonged Postsurgical Analgesia in Lower Abdominal Surgeries

A Phase 4 interventional study of EXPAREL and Placebo in Pain, sponsored by Pacira Pharmaceuticals, Inc. Terminated at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-02.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Treatment

Why this study was terminated
Due to reasons unrelated to safety; primary endpoint signal seen during pre-specified interim analysis.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing Liposomal Bupivacaine in Pain — 5 open to participants now, 5 under way, 2 of them phase 3. Liposomal Bupivacaine · Pain.

Enrollment
17th of 36
67 · median 60
Started
2013
with 1 other
Phase 4
22 of 36
2 open now
Registered
1st of 36
by date
Lead sponsor
7 of 36
Pacira Pharmaceuticals, Inc

Among the 36 studies testing Liposomal Bupivacaine in Pain, this one is the 17th largest by enrollment, is one of 2 that started in 2013, is one of 22 in phase 4, and was the 1st registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

5 of the 36 studies testing Liposomal Bupivacaine in Pain are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About Liposomal Bupivacaine

Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing Liposomal Bupivacaine in Pain, or all of them as a file.
02

Study summary

The purpose of this prospective, blinded assessor, randomized trial is to assess opioid use and patient-reported outcomes of EXPAREL as a foundation in postsurgical pain therapy in Transversus Abdominis Plane (TAP) infiltration in lower abdominal surgical procedures.

Read the detailed description

The purpose of this prospective, blinded assessor, randomized trial is to assess opioid use and patient-reported outcomes of EXPAREL as a foundation in postsurgical pain therapy in Transversus Abdominis Plane (TAP) infiltration in lower abdominal surgical procedures; primary endpoint signal seen during pre-specified interim analysis.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females >18 years of age
  • (ASA) physical status 1-3
  • Undergoing either lower abdominal surgery defined as Laparoscopic Hysterectomy (female), Laparoscopic Myomectomy (female), Laparoscopic Colectomy (male/female)
  • Physically and mentally able to give full to participate in this study and complete all study assessments within the timeframes required (including electronic diaries should patient be discharged prior to day 4)
  • Capable of returning the diary after POD 4 by mail (preferably) or upon follow up visit.

Exclusion criteria

Exclusion Criteria:

  • History of or idiosyncratic reactions to amide-type local anesthetics.
  • Any patient whose anatomy, or surgical procedure, in the opinion of the Investigator, might preclude the potential successful local administration of EXPAREL.
  • Patients who have received any drug within 30 days prior to EXPAREL administration, or planned administration of another investigational product or procedure during their participation in this study.
  • Any chronic condition requiring use of opioids for treatment of a medical condition for 2 weeks or more prior to surgery.
  • Confirmed pregnancy at time of enrollment or breast feeding (females of ).
  • Patients that would constitute a to participation in the study, or cause inability to comply with the study requirements.
  • Any patient with diagnosed or potential disease.
  • Any condition that in the investigator's opinion might be harmed or be a poor candidate for participation in the study (such as patients requiring long acting opioids as part of the induction medications).
  • Initiation of treatment with any of the following medications within 1 month of study drug administration or if the medication(s) are being given to control pain: selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), gabapentin, pregabalin (Lyrica®), or duloxetine (Cymbalta®)
  • History of suspected or known addiction to, or abuse of, illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
67 participants (actual)

Study arms

  • Active comparator
    EXPAREL

    EXPAREL (266mg/20 ml) with 40 mL of 0.9% normal saline for a total volume of 60 mL, 30 mL to be administered to the right TAP and 30 mL to be administered to the left TAP

    Drug: EXPAREL

  • Sham comparator
    Placebo

    The placebo control will be established using a grade-2 sham, no infiltration will occur

    Drug: Placebo

Interventions

  • TAP with EXPAREL

    Also known as: bupivacaine liposome injectable suspension.

  • DrugPlacebo

    Placebo

    Also known as: Placebo using grade-2 sham, no infiltration

06

What researchers measure

Primary outcomes

  1. Total Opioid Consumption Post Surgery (Cumulative Total) Until Discharge Readiness or Post Surgery Day 4

    Total Opioid Consumption Post Surgery (cumulative total) Until Discharge Readiness or Post Surgery Day 4

    Time frame: From surgery through 4 days postsurgery

  2. Overall Benefit of Analgesic Score (OBAS) at Day 3

    Severity of postsurgical pain, satisfaction with pain management, and impact of opioid-related symptom distress measured using the Overall Benefit of Analgesic Score (OBAS) - primary endpoint is mean difference in OBAS at Day 3. (0=minimal pain and 4=maximum imaginable pain)

    Time frame: Postsurgical day 1 through day 3

Secondary outcomes

  1. Extent and Degree of Anesthetic Blockade

    Extent and degree of anesthetic blockage measured using a 5-point sensation scale.

    Time frame: Prior to TAP, immediately postoperatively, and daily through discharge or Day 4

  2. Severity of Postsurgical Pain

    Severity of postsurgical pain measured using an 11-point numerical rating scale (NRS 0-10).

    Time frame: Immediately in PACU postsurgery and prior to pain medication until discharge (or Day 4)

  3. Quality of Recovery

    Measured using the Quality of Recovery 15 questionnaire (QoR-15)

    Time frame: Daily through Post Op Day 4

  4. Frequency of Patient Calls Post-discharge

    Frequency of patient calls post-discharge related to pain and unscheduled hospital/surgeon visits

    Time frame: Post-discharge through 4 days postsurgery

07

Results

Posted Jul 2, 2021

Participant flow

Participant flow — Overall Study
MilestoneEXPARELPlacebo
Started3334
Completed3034
Not completed30
Withdrew: Intra-op findings, etc.30

Outcome measures

PrimaryTotal Opioid Consumption Post Surgery (Cumulative Total) Until Discharge Readiness or Post Surgery Day 4

Total Opioid Consumption Post Surgery (cumulative total) Until Discharge Readiness or Post Surgery Day 4

Time frame:
From surgery through 4 days postsurgery
Reported as:
Mean · Opioid consumption (mg)
Total Opioid Consumption Post Surgery (Cumulative Total) Until Discharge Readiness or Post Surgery Day 4
Opioid consumption (mg)EXPARELPlacebo
Total Opioid Consumption Post Surgery (Cumulative Total) Until Discharge Readiness or Post Surgery Day 43.79 ± NA3.72 ± NA
Statistical analysis
  • EXPAREL vs Placebo · ANCOVA · p = >0.8
PrimaryOverall Benefit of Analgesic Score (OBAS) at Day 3

Severity of postsurgical pain, satisfaction with pain management, and impact of opioid-related symptom distress measured using the Overall Benefit of Analgesic Score (OBAS) - primary endpoint is mean difference in OBAS at Day 3. (0=minimal pain and 4=maximum imaginable pain)

Time frame:
Postsurgical day 1 through day 3
Reported as:
Least squares mean · units on a scale
Overall Benefit of Analgesic Score (OBAS) at Day 3
units on a scaleEXPARELPlacebo
Overall Benefit of Analgesic Score (OBAS) at Day 33.05 ± 0.564.63 ± 0.56
Statistical analysis
  • EXPAREL vs Placebo · Mixed Models Analysis · p = 0.0456
SecondaryExtent and Degree of Anesthetic Blockade

Extent and degree of anesthetic blockage measured using a 5-point sensation scale.

Time frame:
Prior to TAP, immediately postoperatively, and daily through discharge or Day 4

No measurements were reported for this outcome.

SecondarySeverity of Postsurgical Pain

Severity of postsurgical pain measured using an 11-point numerical rating scale (NRS 0-10).

Time frame:
Immediately in PACU postsurgery and prior to pain medication until discharge (or Day 4)

No measurements were reported for this outcome.

SecondaryQuality of Recovery

Measured using the Quality of Recovery 15 questionnaire (QoR-15)

Time frame:
Daily through Post Op Day 4

No measurements were reported for this outcome.

SecondaryFrequency of Patient Calls Post-discharge

Frequency of patient calls post-discharge related to pain and unscheduled hospital/surgeon visits

Time frame:
Post-discharge through 4 days postsurgery

No measurements were reported for this outcome.

Adverse events

Collected over 10 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EXPAREL—1/33 (3%)0/33 (0%)
Placebo—1/34 (2.9%)0/34 (0%)
Most frequent serious events
Most frequent serious events
EventEXPARELPlacebo
Postoperative abdominal hemorrhageGastrointestinal disorders1/330/34
Postoperative anemia exacerbationBlood and lymphatic system disorders0/331/34
Subtherapeutic international normalized ration (INR)Investigations0/331/34

Baseline characteristics

Who met eligibility criteria

Age, Customized
Age, Customized(participants)EXPARELPlaceboTotal
Under 75323365
Over 75112
Sex: Female, Male
Sex: Female, Male(Participants)EXPARELPlaceboTotal
Female272855
Male6612
Region of Enrollment
Region of Enrollment(participants)EXPARELPlaceboTotal
United States333467
08

Study locations

13 sites
  • Florida Hospital
    Winter Park, Florida 32792, United States
  • Memorial Health University Medical Center
    Savannah, Georgia 31404, United States
  • Northwestern University
    Chicago, Illinois 60208, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Berkshire Medical Center
    Pittsfield, Massachusetts 01210, United States
  • University of Minnesota
    Minneapolis, Minnesota 55404, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Duke University
    Durham, North Carolina 27705, United States
  • Fairview Hospital
    Cleveland, Ohio 44111, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • UPMC St. Margaret's Hospital
    Pittsburgh, Pennsylvania 15215, United States
  • St. John Hospital
    Houston, Texas 77081, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Dec 2013 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2021, 7 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2013
First posted
Aug 8, 2013
Start
Aug 2013
Primary completionActual
Dec 2013
CompletionActual
Feb 2014
Results first posted
Jul 2, 2021
Last update
Jul 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01919190
Responsible party
Sponsor
First posted
Aug 8, 2013
Start date
Aug 2013
Primary completion
Dec 2013
Completion
Feb 2014
Results posted
Jul 2, 2021
Last update
Jul 2, 2021

Study contacts

Kay Warnott, RN
study director · Pacira Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion